Clinical TrialsThe BESTOW trial completed enrollment four months ahead of schedule, as the transplant community is demanding a better immunosuppression treatment option.
Drug EfficacyRecent data from the trial evaluating tegoprubart as part of an immunosuppressive regimen to prevent islet-cell-transplant rejection appear compelling, with the first two subjects treated achieving insulin independence.
Financial PositionEledon reported having $124.9M in cash, cash equivalents, and short-term investments, which is expected to fund operations through the end of the year.